Cardiometabolic Health Congress to offer latest in cardiometabolic care, education

Those attending this year’s Cardiometabolic Health Congress will gain insight into the latest developments across the spectrum of multidisciplinary care, from diabetes and obesity to hypertension and dyslipidemia management, all from a roster of leading experts.

The 11^th annual meeting is expected to bring approximately 1,200 cardiologists, endocrinologists and other health care professionals to the Sheraton Hotel in Boston from Oct. 5 to 8 to learn about the latest scientific and clinical developments in cardiometabolic medicine.

Attendees will have access to 4 days of scientific sessions, case presentations and workshops, as well as a “meet the experts” lounge and both CME and non-CME symposia.

“This is a very user-friendly meeting for the attendees,” Robert H. Eckel, MD, professor of medicine and Charles A. Boettcher chair in atherosclerosis at the University of Colorado, Anschutz Medical Campus, and a meeting co-chair, told Endocrine Today. “The overlap between metabolic diseases, such as diabetes, lipid disorders and obesity, relate very much to CV diseases. The whole waterfront is covered here, from risk factors, to interventional and clinical trials. For attendees, there are things that can be applied immediately to their practice that relate to what’s going on at the cutting edge of cardiometabolic medicine.”

Robert H. Eckel

This year’s Cardiometabolic Health Congress (CMHC) meeting will highlight a number of important developments over the past year, including nuances of the SPRINT trial and its application to clinical practice, and new outcome trials showing not only safety, but reduced CV risk when using SGLT2 inhibitors and GLP-1 receptor agonists to treat diabetes, said George L. Bakris, MD, professor of medicine and director of the ASH Comprehensive Hypertension Center at University of Chicago Medicine and a member of the Cardiology Today Editorial Board.

George L. Bakris

“It has been said by many participants that their attendance at the meeting usually results in two to three key messages that enhance their practice,” Bakris, also a meeting co-chair, told Endocrine Today. “The latest innovations and clinical trials, as well as guidelines, are discussed in a practical manner, focusing on the message for the practicing clinician. The background and intent of national CV, renal and diabetes guidelines is focused on practical implementations, as are results from clinical trials.”

Other meeting highlights include:

This year, CMHC will include two new practice management workshops: "Capital — What Health Care Professionals Need to Know About Money" and "Leadership and Management for Healthcare Professionals," as well as a symposium on nutritional interventions in clinical practice, all taking place on Wednesday, Oct 5.
Keynote speaker Steven E. Nissen, MD, MACC, chairman of the department of cardiovascular medicine at Cleveland Clinic’s Heart & Vascular Institute and a member of the Cardiology Today Editorial Board, will open the meeting with his presentation, "Intravascular Ultrasound Insights into the Regression and Progression of Coronary Atherosclerosis." Other keynotes will be presented by Peter Libby, MD, senior physician at Brigham and Women's Hospital and professor of medicine at Harvard Medical School and editor of the Vascular Medicine section of Cardiology Today, speaking on the increasing prevalence of triglycerides as a CV risk factor; Suzanne Oparil, MD, professor of medicine at University of Alabama at Birmingham School of Medicine, presenting an update of the SPRINT trial, including clinical implications; C. Ronald Kahn, MD, professor of medicine at Harvard Medical School and chief academic officer at the Joslin Diabetes Center, discussing the gut microbiome as a modifier of insulin resistance and metabolic syndrome; and Subodh Verma, MD, PhD, a cardiac surgeon at St. Michael’s Hospital in Toronto, Canada, and professor of surgery, pharmacology and toxicology at the University of Toronto, offering insight on obesity fat distribution and CV risk.
Clyde W. Yancy, MD, chief of cardiology in the department of medicine at Northwestern Feinberg School of Medicine, will discuss HF in the context of the SPRINT trial on Friday, Oct. 7, and Bakris will offer perspective on SGLT-2 inhibitors as a second-line therapy in diabetes.
Lee M. Kaplan, MD, PhD, director of the Obesity, Metabolism and Nutrition Institute at Massachusetts General Hospital, and Francesco Rubino, MD, professor and chair of bariatric and metabolic surgery at King's College London, will discuss the latest on metabolic surgery and Caroline Apovian, MD, professor of medicine and pediatrics at Boston University School of Medicine, will explore the latest information on obesity treatments and pharmacology guidelines for clinicians on Saturday, Oct. 8.

Sessions are organized so that similar topics take place on each individual day. In addition, the meeting will include a CMHC exhibitor showcase, featuring exhibits from leading pharmaceutical, medical device, technology and health and wellness companies.

The Cardiology Today, Endocrine Today and Healio.com staff will provide coverage from CMHC, including reports on the sessions described above and others, onsite video interviews and much more. For more information on the CMHC agenda and registration, visit www.cardiometabolichealth.org. – by Regina Schaffer

Disclosure: Healio.com is a platinum media partner of the Cardiometabolic Health Congress.